Renaissance Technologies LLC lowered its position in shares of Amedisys Inc (NASDAQ:AMED) by 29.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 262,300 shares of the company’s stock after selling 107,101 shares during the period. Renaissance Technologies LLC’s holdings in Amedisys were worth $11,182,000 at the end of the most recent reporting period.
Other large investors also recently made changes to their positions in the company. Royal Bank of Canada raised its stake in shares of Amedisys by 10,428.0% in the second quarter. Royal Bank of Canada now owns 5,264 shares of the company’s stock worth $266,000 after buying an additional 5,214 shares during the period. Kalmar Investments Inc. DE bought a new stake in shares of Amedisys during the third quarter worth $12,731,000. Great West Life Assurance Co. Can raised its stake in shares of Amedisys by 1.9% in the third quarter. Great West Life Assurance Co. Can now owns 38,028 shares of the company’s stock worth $1,804,000 after buying an additional 725 shares during the period. Wells Fargo & Company MN raised its stake in shares of Amedisys by 3.2% in the third quarter. Wells Fargo & Company MN now owns 1,730,964 shares of the company’s stock worth $82,117,000 after buying an additional 53,652 shares during the period. Finally, Quantbot Technologies LP raised its stake in shares of Amedisys by 717.9% in the third quarter. Quantbot Technologies LP now owns 2,699 shares of the company’s stock worth $128,000 after buying an additional 2,369 shares during the period. 94.88% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Amedisys Inc (NASDAQ:AMED) opened at 50.25 on Tuesday. The firm has a 50-day moving average of $48.23 and a 200 day moving average of $45.28. Amedisys Inc has a 12-month low of $34.58 and a 12-month high of $55.16. The stock has a market capitalization of $1.69 billion, a price-to-earnings ratio of 45.68 and a beta of 1.43.
Amedisys (NASDAQ:AMED) last announced its quarterly earnings data on Tuesday, February 28th. The company reported $0.44 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.39 by $0.05. Amedisys had a net margin of 2.93% and a return on equity of 11.94%. The business had revenue of $366.30 million for the quarter, compared to analyst estimates of $368.14 million. During the same period last year, the business earned $0.40 EPS. The company’s revenue was up 8.2% on a year-over-year basis. Equities analysts forecast that Amedisys Inc will post $2.02 earnings per share for the current fiscal year.
AMED has been the topic of a number of research analyst reports. Craig Hallum initiated coverage on shares of Amedisys in a report on Friday, December 16th. They set a “buy” rating and a $48.00 price objective on the stock. Zacks Investment Research raised shares of Amedisys from a “sell” rating to a “hold” rating in a report on Monday, January 9th. Jefferies Group LLC set a $50.00 price objective on shares of Amedisys and gave the company a “buy” rating in a report on Friday, January 13th. Benchmark Co. initiated coverage on shares of Amedisys in a report on Friday, January 27th. They set a “hold” rating and a $50.00 price objective on the stock. Finally, Mizuho boosted their price objective on shares of Amedisys from $33.00 to $50.00 and gave the company a “neutral” rating in a report on Wednesday, March 1st. One analyst has rated the stock with a sell rating, five have issued a hold rating and four have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $54.50.
Amedisys, Inc (Amedisys) is a provider of home health and hospice services. The Company offers home health services to the chronic, co-morbid, aging American population. The Company operates through three segments: home health, hospice and personal care. The Company’s home health segment delivers a range of services in the homes of individuals recovering from surgery, have a chronic disability or terminal illness or need assistance with completing important personal tasks.
Want to see what other hedge funds are holding AMED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amedisys Inc (NASDAQ:AMED).